A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode
4期
已完成
NCT00277212
| 适应症 | Bipolar Disorder |
|---|
| 分期 | 4期 |
|---|
| 申办方 | Otsuka Pharmaceutical Development & Commercialization, Inc. |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 1,169 人 |
|---|
| 干预（药物） | Lamotrigine + Aripiprazole, Lamotrigine + Placebo |
|---|
| 开始日期 | 2005年12月1日 |
|---|
| 完成日期 | 2009年7月1日 |
|---|
| 结果公布日 | 2010年10月20日 |
|---|
摘要
Efficacy of Aripiprazole in Combination with Lamotrigine in the Long-Term Maintenance Treatment of Bipolar I Disorder in Outpatients with Recent Manic or Mixed Episode
Proportion of Participants Not Experiencing Relapse Through Week 52 in the Double-Blind Relapse Assessment Phase (Phase 2)
Weeks 0, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 · Proportion of Participants
| Phase 2 Double-Blind Treatment: Lamotrigine + Placebo | 1.00 Proportion of Participants |
|---|
| Phase 2 Double-Blind Treatment: Lamotrigine + Aripiprazole | 1.00 Proportion of Participants |
|---|
| Phase 2 Double-Blind Treatment: Lamotrigine + Placebo | 0.98 Proportion of Participants |
|---|
| Phase 2 Double-Blind Treatment: Lamotrigine + Aripiprazole | 0.98 Proportion of Participants |
|---|
| Phase 2 Double-Blind Treatment: Lamotrigine + Placebo | 0.97 Proportion of Participants |
|---|
| Phase 2 Double-Blind Treatment: Lamotrigine + Aripiprazole | 0.96 Proportion of Participants |
|---|
| p-value | 0.058 |
|---|
| Cox Proportional Hazard | 0.552 (95% CI 0.296–1.030) |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。